By Robert M. DiSogra

Audiologists have known about the ototoxicity of quinine (and its derivatives) and antibiotics (macrolide and aminoglycoside) for decades. But we have never seen the combined use of two drugs, each with known ototoxic potential, being used as an intervention strategy for the coronavirus pandemic (COVID-19).

In an effort to combat the coronavirus (COVID-19), front-line physicians are repurposing two drugs: hydroxychloroquine (commonly used for malaria and rheumatoid arthritis) and azithromycin (a macrolide antibiotic used to treat common infections of the respiratory system, the ear and the eye). Both drugs are known ototoxic agents; however, there is no published research about the synergistic ototoxic effects of these drugs in treating COVID-19.

At the present time, it is not known if hearing loss and/or tinnitus will be a late onset side effect of this COVID-19 drug intervention. Therefore, case history questions will need to be added to accommodate this new population of patients.

Read the full article online.

Share this

Related Posts

Cortical Changes in Total and Partial Vestibular Dysfunction, As Measured by EEG

Where do U.S. Adults Obtain Their Usual Healthcare?

Use of Dietary Supplements in the United States

Recent Posts

Cortical Changes in Total and Partial Vestibular Dysfunction, As Measured by EEG

Study Supports Expanded Candidacy for Pediatric Cochlear Implantation For children less than two years of age, current Food and Drug Administration (FDA) candidacy criteria for…

Read More

Academy Submits Comments on MPFS Proposed Rule CY 2027

On behalf of the membership, the American Academy of Audiology has submitted comments on the Centers for Medicare and Medicaid Services’ (CMS) Calendar Year (CY)…

Read More

Where do U.S. Adults Obtain Their Usual Healthcare?

While we know that primary care providers can be a source of referrals for audiologic care, have you wondered how many individuals have a regular…

Read More